Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc.
The interactions between these components, which are divided into anti-tumor and pro …

Monoclonal antibodies (mAbs) as biological macromolecules have been remarked the large
and growing pipline of the pharmaceutical market and also the most promising tool in …

Emerging evidence indicates that the induction of radiotherapy (RT) on the immunogenic
cell death (ICD) is not only dependent on its direct cytotoxic effect, changes in the tumor …

Tumor heterogeneity has been associated with immunotherapy and targeted drug
resistance in hepatocellular carcinoma (HCC). However, communications between tumor …

Background Nrf2, an essential and fascinating transcription factor, enjoys a dual property in
the occurrence and development of inflammation and cancer. For over two decades …

Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors
have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as …

Cancer immunotherapy moderates the immune system's ability to fight cancer. Due to its
extreme complexity, scientists are working to put together all the puzzle pieces to get a …

In recent years, the use of immune checkpoint inhibitors (ICIs) in combination with approved
or experimental vaccines has proven to be a promising approach to improve vaccine …

Adaptive T-cell immunotherapy holds great promise for the successful treatment of leukemia,
as well as other types of cancers. More recently, it was also shown to be an effective …

Natural killer T (NKT) cells are a specific T cell subset known to express the αβ-T cell
receptor (TCR) for antigens identification and express typical NK cell specifications, such as …